FDA Approval of ZUSDURI
ZUSDURI was approved for adults with recurrent low-grade intermediate risk non-muscle invasive bladder cancer, marking a significant milestone for UroGen and offering a new treatment paradigm.
Strong JELMYTO Revenue Growth
JELMYTO achieved net product revenues of $24.2 million in Q2 2025, representing an 11% increase over the same period in 2024.
Expansion of Sales Force
The sales team expanded from 50 to 82 territories to support the launch of ZUSDURI, positioning the company to reach a broader market.
Positive Clinical Data for ZUSDURI
In the pivotal Phase III ENVISION trial, 79% of patients achieved a complete response at 3 months, with a 24-month duration of response of 72.2%.
Robust Cash Position
UroGen maintains a strong balance sheet with $161.6 million in cash, cash equivalents, and marketable securities as of June 30, 2025.